Group 1 - Shengxiang Bio plans to increase its investment in Hunan Shengwei Kunteng Biotechnology Co., Ltd. by 100 million yuan to enhance its industrial chain layout in the POCT field, resulting in a 44.6441% stake in Shengwei Kunteng after the investment [1] - Yaguang Technology's subsidiary Chengdu Yaguang signed a product pre-production agreement worth 101 million yuan, accounting for 10.56% of the company's audited revenue for the last fiscal year [1] Group 2 - Chutianlong's shareholder plans to reduce its stake by up to 3%, equating to 13.83 million shares, due to personal funding needs [2] - Naipu Mining intends to invest up to 45 million USD in Swiss Veritas Resources AG, acquiring a 22.5% stake to extend its industrial chain [2][3] Group 3 - Diri Medical's shareholder plans to reduce its stake by up to 3%, totaling 814.83 thousand shares, due to funding needs [4] - Kangtai Medical's controlling shareholder plans to reduce its stake by up to 2.99%, equating to 12 million shares [5] Group 4 - Iwu Bio's controlling shareholder plans to transfer up to 450 thousand shares through block trading, representing 0.86% of the total share capital [7] - Guokai Hengtai's four shareholders plan to collectively reduce their stake by up to 4.7%, totaling 22.94 million shares [9] Group 5 - *ST Zhongcheng submitted a hearing application to the Shenzhen Stock Exchange in response to a delisting notice [10] - Donghua Software's actual controller and associated parties plan to reduce their stake by up to 1%, totaling 32.05 million shares [12] Group 6 - Shandong Molong's shareholder reduced its H-share holdings by 107 million shares, representing 13.39% of the total share capital [12] - Yinbang Co.'s shareholder plans to reduce its stake by up to 1%, totaling 821.92 thousand shares [13] Group 7 - Jinxinnong reported April sales of 10.65 million pigs, generating sales revenue of 139 million yuan, with an average selling price of 15.05 yuan per kilogram [14] - Dongfang Jiasheng purchased 9.54 million shares of Zhonggu Logistics for approximately 99.72 million yuan, representing 4.18% of the company's net assets [15] Group 8 - Linglong Tire's controlling shareholder received a financing commitment of up to 270 million yuan for stock repurchase [16] - Wuchan Jinlun's shareholder plans to reduce its stake by up to 3%, totaling 619.77 thousand shares [18] Group 9 - Pengyao Environmental's directors and executives plan to collectively reduce their stake by up to 0.07% [19] - Ruihu Mould's controlling shareholder plans to reduce its stake by up to 1.92%, totaling 401.89 thousand shares [20] Group 10 - Electric Alloy's shareholder plans to reduce its stake by up to 0.63%, totaling 210.88 thousand shares [22] - Shanghai Xinyang's controlling shareholder plans to reduce its stake by up to 0.64%, totaling 200 thousand shares [24] Group 11 - Sujiao Ke's controlling shareholder plans to acquire up to 2% of the company's shares from a fund [26] - Heyuan Bio's shareholders plan to reduce their stake by up to 1%, totaling 649.04 thousand shares [27]

中国经济网北京5月9日讯和元生物(688238.SH)昨日晚间发布公告称，近日，公司收到股东股东浙江华睿盛银创业投资有限公司(以下 简称"华睿盛银")及其一致行动人出具的《关于股东减持计划的告知函》。 公司股东华睿盛银及其一致行动人拟通过集中竞价、大宗交易的方式减持所持公司股份，减持股份数量合计不超过6,490,367股，占 公司总股本比例不超过1%。上述减持自公告披露之日起15个交易日后的3个月内进行。 其中，华睿盛银计划减持数量不超过1,100,000股，计划减持比例不超过0.1695%；诸暨富华产业转型升级基金合伙企业(有限合伙)(以 下简称"诸暨富华")计划减持数量不超过1,000,000股，计划减持比例不超过0.1541%；浙江华睿胡庆余堂健康产业投资基金合伙企业 (有限合伙)(以下简称"华睿胡庆余堂")计划减持数量不超过1,000,000股，计划减持比例不超过0.1541%；浙江华睿火炬创业投资合伙 企业(有限合伙)(以下简称"华睿火炬")计划减持数量不超过1,910,275股，计划减持比例不超过0.2943%；杭州华睿嘉银股权投资合伙 企业(有限合伙)(以下简称"华睿嘉银")计划减持数量不超过1 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-037 和元生物技术（上海）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，和元生物技术(上海)股份有限公司(以下简称"公司") 股东浙江华睿盛银创业投资有限公司（以下简称"华睿盛银"）持有公司股份 19,672,145 股，占公司总股本的比例为 3.0310%；诸暨富华产业转型升级基金合 伙企业（有限合伙）（以下简称"诸暨富华"）持有公司股份 7,052,900 股，占 公司总股本的比例为 1.0867%；浙江华睿胡庆余堂健康产业投资基金合伙企业 （有限合伙）（以下简称"华睿胡庆余堂"）持有公司股份 4,614,693 股，占公 司总股本的比例为 0.7110%；浙江华睿火炬创业投资合伙企业（有限合伙）（以 下简称"华睿火炬"）持有公司股份 3,916,087 股，占公司总股本的比例为 0.6034%；杭州华睿嘉银股权投资合伙企业（有限合伙）（以下简称"华 ...

Jin Mao Law Firm 金 茂 律 師 事 務 所 40th Floor Rund Center 222 East Van An Road, Shanghai 200002, PR 海市延安东路 227 号外滩中 Tel/电话:(8621) 6249 6040 Fax/传真:(8621) 6248 2266 Website/网址: www.jinmao.com.cn 上海市金茂律师事务所 关于和元生物技术(上海)股份有限公司 2024年年度股东大会之法律意见书 致:和元生物技术(上海)股份有限公司 和元生物技术(上海)股份有限公司(以下简称"公司")2024年年度股东大 会(以下简称"本次股东大会")于 2025年5月8日下午在公司会议室召开。上 海市金茂律师事务所(以下简称"本所")经公司聘请并接受公司委托,委派马也 律师、赵可沁律师(以下简称"本所律师")出席本次股东大会,并根据《中华人 民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")、中国证券监督管理委员会公布的《上市公司股东会规则》 (以下简称"《股东会规则》")等相关法律、法规和规范性文件以 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-036 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 100 | | --- | --- | | 普通股股东人数 | 100 | | 2、出席会议的股东所持有的表决权数量 | 176,805,041 | | 普通股股东所持有表决权数量 | 176,805,041 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 28.0505 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 28.0505 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长潘讴东先生主持，采用现场表决与 （一） 股东大会召开的时间：2025 年 5 月 8 日 （二） 股东大会召开的地点：上海市临港新片区沧海路 3888 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 和元生物技 ...

和元生物公告，股东华睿盛银及其一致行动人计划减持不超过649.04万股，占公司总股本的1%。减持 期间为2025年5月30日至2025年8月29日，减持方式为集中竞价和大宗交易。 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of He Yuan Biological Technology Co., Ltd., which focuses on gene therapy and related services [1][2] - As of the first quarter of 2025, the company reported a revenue of 52.85 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, representing a year-on-year decline of 41.04% [1] - The company's gross profit margin was reported at -36.44%, indicating challenges in profitability [1] Group 2 - He Yuan Biological has a current market capitalization of 3.816 billion yuan and a price-to-book ratio of 2.35 [1][2] - The company is among seven institutions holding shares, with a total of 83.47 million shares valued at approximately 459 million yuan [1] - The industry average price-to-earnings ratio (PE) is 38.66, while He Yuan Biological's trailing PE is -11.25, indicating a significant underperformance compared to industry peers [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of He Yuan Biological Technology Co., Ltd., a biotech company focused on gene therapy [1][2] - As of the first quarter of 2025, He Yuan reported a revenue of 52.85 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, representing a 41.04% decline compared to the previous year [1] - The company's gross profit margin was reported at -36.44%, indicating challenges in profitability [1] Group 2 - He Yuan's current stock price is 5.42 yuan, with a market capitalization of 3.518 billion yuan and a price-to-book ratio of 2.17 [1] - The company is among seven institutions holding shares, with a total of 83.47 million shares valued at 459 million yuan [1] - In comparison to industry averages, He Yuan's price-to-earnings ratio (TTM) is -10.37, while the industry average is 40.74 [2]

国泰海通证券股份有限公司 关于和元生物技术（上海）股份有限公司 2024 年度持续督导年度跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：和元生物 | | --- | --- | | 保荐代表人姓名：陈恒瑞、张子慧 | 被保荐公司代码：688238.SH | 重大事项提示 2024 年度，公司实现营业收入 24,814.92 万元，同比增长 21.16%，实现归属 于母公司所有者的净利润-32,181.30 万元，实现归属于母公司所有者的扣除非经 常性损益的净利润-33,591.24 万元，较上年同期下降。报告期内，公司 CDMO 业 务继续受宏观环境变化、产业状况、下游需求等因素影响，执行订单价格仍处于 较低水平，而公司临港产业基地一期已全面投产，产能释放需要时间，折旧摊销 成本、能耗成本、行政办公费用以及场地搬迁等原因导致运营成本费用同比大幅 增长，报告期内细胞和基因治疗 CDMO 业务营业毛利、净利润继续出现负值， 较上年度亏损增加。未来如果国内市场景气度回暖不及预期，生物医药投融资环 境持续低迷，下游 CGT CDMO 客户新药研发动力无法得到资金推动，而公司以 国内 CGT ...

Core Insights - The company has evolved from a small 12 square meter incubation base to a production platform of over 77,000 square meters in Lingang, becoming a pioneer in the cell and gene therapy (CGT) sector [2][4] - The chairman emphasizes the importance of perseverance and innovation in driving the company's growth and success in the CGT field [2][3] Company Development - The company started its journey in 2006, initially providing adenoviral vector services to research institutions and gradually expanding its operations [3] - The company has successfully transitioned from a small startup to a major player in the CGT industry, benefiting from a solid foundation laid in its early years [3][4] Capital Market Interaction - The company went public on the New Third Board in 2016, which provided sufficient funding to expand its capabilities in the gene therapy CDMO sector [4] - In 2022, the company successfully listed on the Sci-Tech Innovation Board, and by 2024, its Lingang base's first phase construction was completed and fully operational [4] Industry Trends - Cell and gene therapy is recognized as the "third revolution" in life sciences, with increasing applications in treating various diseases [5] - The company is focused on overcoming challenges in the CGT industry by enhancing its core technologies and expanding its intellectual property protection [5][6] Technological Advancements - The company aims to improve the development and production processes of gene therapy vectors, including the research of AAV viral vectors for rare diseases and the development of non-viral gene therapy vectors [5][6] - The company is investing in large-scale GMP production and quality control technologies to address bottlenecks in the CGT production process [6] Future Strategy - The company plans to leverage its Lingang base to provide comprehensive CRO/CDMO solutions, aiming to reduce costs and accelerate drug development [7][8] - Future initiatives include expanding into stem cell therapy and regenerative medicine, establishing a full-service capability from cell storage to clinical transformation [8] - The company is also looking to grow its CRO and CDMO services internationally, with potential mergers and collaborations to diversify its product offerings in cell and gene therapy [8]